Development of gene therapy for thalassemia

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 11, 2012, Pages

  Nienhuis, Arthur W ^a   Persons, Derek A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; ENVELOPE PROTEIN; HEMOGLOBIN ALPHA CHAIN; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN EPSILON CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; LENTIVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; GLOBIN;

ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; ERYTHROID CELL; EXPRESSION VECTOR; GENE ACTIVATION; GENE EXPRESSION; GENE INSERTION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GLOBIN GENE; HEMATOPOIETIC STEM CELL; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; MYELOID LEUKEMIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; REGULATOR GENE; T CELL LEUKEMIA; THALASSEMIA; THALASSEMIA INTERMEDIA; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; RETROVIRUS; REVIEW; STEM CELL;

HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GAMMARETROVIRUS; GENETIC THERAPY; GENETIC VECTORS; GLOBINS; HUMANS; LENTIVIRUS; LOCUS CONTROL REGION; STEM CELLS; THALASSEMIA;

EID: 84877152805     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a011833     Document Type: Article

References (151)

1. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
2. Aiuti A, Cassani B, Andolfi G, Mirolo M, Biasco L, Recchia A, Urbinati F, ValaccaC, Scaramuzza S, Aker M, et al. 2007. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 117: 2233-2240.
3. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, et al. 2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360: 447-458.
4. Aker M, Tubb J, Groth AC, Bukovsky AA, Bell AC, Felsenfeld G, Kiem HP, Stamatoyannopoulos G, Emery DW. 2007. Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther 18: 333-343.
5. Arumugam PI, Scholes J, Perelman N, Xia P, Yee JK, Malik P. 2007. Improved human β-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol Ther 15: 1863-1871.
6. Arumugam PI, Urbinati F, Velu CS, Higashimoto T, Grimes HL, Malik P. 2009. The 3′ region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity. PLoS ONE 4: e6995.
7. Bank A, Dorazio R, Leboulch P. 2005. A phase I/II clinical trial of β-globin gene therapy for β-thalassemia. Ann NY Acad Sci 1054: 308-316.
8. Beard BC, Trobridge GD, Ironside C, McCune JS, Adair JE, Kiem HP. 2010. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest 120: 2345-2354.
9. Bell AC, West AG, Felsenfeld G. 1999. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 98: 387-396.
10. Biasco L, Baricordi C, Aiuti A. 2012. Retroviral integrations in gene therapy trials. Mol Ther 20: 709-716.
11. Biffi A, Naldini L. 2007. Novel candidate disease for gene therapy: Metachromatic leukodystrophy. Expert Opin Biol Ther 7: 1193-1205.
12. Biffi A, Bartolomae CC, Cesana D, Cartier N, Aubourg P, Ranzani M, Cesani M, Benedicenti F, Plati T, Rubagotti E, et al. 2011. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117: 5332-5339.
13. Blouin MJ, Beauchemin H, Wright A, De Paepe M, Sorette M, Bleau AM, Nakamoto B, Ou CN, Stamatoyannopoulos G, Trudel M. 2000. Genetic correction of sickle cell disease: Insights using transgenic mouse models. Nat Med 6: 177-182.
14. Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA, Böhm M, Nowrouzi A, Ball CR, Glimm H, et al. 2010. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 363: 1918-1927.
15. Braun CJ, Boztug K, Schmidt M, Albert MH, Schwarzer A, Paruzynski A, ModlichU, Beier R, Gobring G, Naundorf S, et al. 2011. Efficacy of gene therapy for Wiskott-Aldrich syndrome. Blood 118: 81.
16. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, et al. 2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
17. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Bougnères P, Schmidt M, KalleCV, Fischer A, Cavazzana-Calvo M, Aubourg P. 2012. Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. Methods Enzymol 507: 187-198.
18. - human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci 96: 2988-2993.
19. + hematopoietic cells. Blood 110: 1770-1778.
20. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, Down J, Denaro M, Brady T, Westerman K, et al. 2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467: 318-322.
21. Cesana D, Sgualdino J, Rudilosso L, Merella S, Naldini L, Montini E. 2012. Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 122: 1667-1676.
22. Chang JC, Liu D, Kan YW. 1992. A 36-base-pair core sequence of locus control region enhances retrovirally transferred human β-globin gene expression. Proc Natl Acad Sci 89: 3107-3110.
23. Chung JH, Whiteley M, Felsenfeld G. 1993. A 5′ element of the chicken β-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 74: 505-514.
24. Chung JH, Bell AC, Felsenfeld G. 1997. Characterization of the chicken β-globin insulator. Proc Natl Acad Sci 94: 575-580.
25. min-globin genes in embryonic stem cells. Proc Natl Acad Sci 92: 9259-9263.
26. Cone RD, Weber-Benarous A, Baorto D, Mulligan RC. 1987. Regulated expression of a complete human β-globin gene encoded by a transmissible retrovirus vector. Mol Cell Biol 7: 887-897.
27. Cooray S, Howe SJ, Thrasher AJ. 2012. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol 507: 29-57.
28. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm H, Gyapay G, Prum B, Fraser CC, et al. 2007. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225-2232.
29. Deichmann A, Brugman MH, Bartholomae CC, Schwarzwaelder K, VerstegenMM, Howe SJ, Arens A, Ott MG, Hoelzer D, Seger R, et al. 2011. Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther 19: 2031-2039.
30. Dickson J, Gowher H, Strogantsev R, Gaszner M, Hair A, Felsenfeld G, West AG. 2010. VEZF1 elements mediate protection from DNA methylation. PLoS Genet 6: e1000804.
31. Dzierzak EA, Papayannopoulou T, Mulligan RC. 1988. Lineage-specific expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 331: 35-41.
32. Edelman LB, Fraser P. 2012. Transcription factories: Genetic programming in three dimensions. Curr Opin Genet Dev 22: 110-114.
33. Ellis J, Pannell D. 2001. The β-globin locus control region versus gene therapy vectors: A struggle for expression. Clin Genet 59: 17-24.
34. Emery DW. 2011. The use of chromatin insulators to improve the expression and safety of integrating gene transfer vectors. Hum Gene Ther 22: 761-774.
35. Aγ-globin. Blood Cells Mol Dis 24: 322-339.
36. Emery DW, Yannaki E, Tubb J, Stamatoyannopoulos G. 2000. A chromatin insulator protects retrovirus vectors from chromosomal position effects. Proc Natl Acad Sci 97: 9150-9155.
37. Emery DW, Yannaki E, Tubb J, Nishino T, Li Q, Stamatoyannopoulos G. 2002. Development of virus vectors for gene therapy of β chain hemoglobinopathies: Flanking with a chromatin insulator reduces γ-globin gene silencing in vivo. Blood 100: 2012-2019.
38. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222.
39. Forrester WC, Takegawa S, Papayannopoulou T, Stamatoyannopoulos G, Groudine M. 1987. Evidence for a locus activation region: The formation of developmentally stable hypersensitive sites in globin-expressing hybrids. Nucleic Acids Res 15: 10159-10177.
40. Fragkos M, Anagnou NP, Tubb J, Emery DW. 2005. Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human γ-globin. Gene Ther 12: 1591-1600.
41. Galy A, Thrasher AJ. 2011. Gene therapy for the Wiskott-Aldrich syndrome. Curr Opin Allergy Clin Immunol 11: 545-550.
42. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, et al. 2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
43. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Adams S, Howe SJ, Al GhonaiumA, Bayford J, Brown L, Davies EG, et al. 2011a. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 3: 97ra79.
44. Gaspar HB, Cooray S, Gilmour KC, Parsley KL, Zhang F, Adams S, Bjorkegren E, Bayford J, Brown L, Davies EG, et al. 2011b. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 3: 97ra80.
45. Ghirlando R, Giles K, Gowher H, Xiao T, Xu Z, Yao H, Felsenfeld G. 2012. Chromatin domains, insulators, and the regulation of gene expression. Biochim Biophys Acta 1819: 644-651.
46. Giles KE, Gowher H, Ghirlando R, Jin C, Felsenfeld G. 2010. Chromatin boundaries, insulators, and long-range interactions in the nucleus. Cold Spring Harb Symp Quant Biol 75: 79-85.
47. Grez M, Reichenbach J, Schwäble J, Seger R, Dinauer MC, Thrasher AJ. 2011. Gene therapy of chronic granulomatous disease: The engraftment dilemma. Mol Ther 19: 28-35.
48. Grosveld F, van Assendelft GB, Greaves DR, Kollias G. 1987. Position-independent, high-level expression of the human β-globin gene in transgenic mice. Cell 51: 975-985.
49. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
50. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
51. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118: 3132-3142.
52. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, MartinacheC, Rieux-Laucat F, Latour S, Belohradsky BH, et al. 2010. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363: 355-364.
53. Hanawa H, Hargrove PW, Kepes S, Srivastava DK, Nienhuis AW, Persons DA. 2004. Extended β-globin locus control region elements promote consistent therapeutic expression of a γ-globin lentiviral vector in murine β-thalassemia. Blood 104: 2281-2290.
54. Hanawa H, Yamamoto M, Zhao H, Shimada T, Persons DA. 2009. Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken β-globin locus HS4 insulator element. Mol Ther 17: 667-674.
55. Hargrove PW, Kepes S, Hanawa H, Obenauer JC, Pei D, Cheng C, Gray JT, NealeG, Persons DA. 2008. Globin lentiviral vector insertions can perturb the expression of endogenous genes in β-thalassemic hematopoietic cells. Mol Ther 16: 525-533.
56. + cells with HIV-1-derived lentiviral vectors. Mol Ther 2: 71-80.
57. Heckl D, Schwarzer A, Haemmerle R, Steinemann D, Rudolph C, Skawran B, Knoess S, Krause J, Li Z, Schlegelberger B, et al. 2012. Lentiviral vector induced insertional haploinsufficiency of Ebf1 causes murine leukemia. Mol Ther 20: 1187-1195.
58. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, KempskiH, Brugman MH, Pike-Overzet K, Chatters SJ, de Ridder D, et al. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 3143-3150.
59. Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, Eaves CJ, Cavilla B, Wadsworth LD, Beuzard Y, Bouhassira EE, et al. 2002. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci 99: 14380-14385.
60. Imren S, Fabry ME, Westerman KA, Pawliuk R, Tang P, Rosten PM, Nagel RL, Leboulch P, Eaves CJ, Humphries RK. 2004. High-level β-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J Clin Invest 114: 953-962.
61. Karlsson S, Van Doren K, Schweiger SG, Nienhuis AW, Gluzman Y. 1986. Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. EMBO J 5: 2377-2385.
62. Karlsson S, Papayannopoulou T, Schweiger SG, Stamatoyannopoulos G, Nienhuis AW. 1987. Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein. Proc Natl Acad Sci 84: 2411-2415.
63. Kiem HP, Sellers S, Thomasson B, Morris JC, Tisdale JF, Horn PA, Hematti P, Adler R, Kuramoto K, Calmels B, et al. 2004. Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: No progression to clonal hematopoiesis or leukemia. Mol Ther 9: 389-395.
64. Kim YS, Wielgosz MM, Hargrove P, Kepes S, Gray J, Persons DA, Nienhuis AW. 2010. Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins. Mol Ther 18: 1310-1317.
65. + cells enhances their proliferative potential and ability to engraft immunodeficient mice. Exp Hematol 40: 84-91.
66. Kolovos P, Knoch TA, Grosveld FG, Cook PR, Papantonis A. 2012. Enhancers and silencers: An integrated and simple model for their function. Epigenetics Chromatin 5: 1.
67. Larochelle A, Choi U, Shou Y, Naumann N, Loktionova NA, Clevenger JR, Krouse A, Metzger M, Donahue RE, Kang E, et al. 2009. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest 119: 1952-1963.
68. Larochelle A, Gillette JM, Desmond R, Ichwan B, Cantilena A, Cerf A, Barrett AJ, Wayne AS, Lippincott-Schwartz J, Dunbar CE. 2012. Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain. Blood 119: 1848-1855.
69. Leboulch P, Huang GM, Humphries RK, Oh YH, Eaves CJ, Tuan DY, London IM. 1994. Mutagenesis of retroviral vectors transducing human β-globin gene and β-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J 13: 3065-3076.
70. Levasseur DN, Ryan TM, Pawlik KM, Townes TM. 2003. Correction of a mouse model of sickle cell disease: Lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102: 4312-4319.
71. Li Q, Emery DW, Fernandez M, Han H, Stamatoyannopoulos G. 1999. Development of viral vectors for gene therapy of β-chain hemoglobinopathies: Optimization of a γ-globin gene expression cassette. Blood 93: 2208-2216.
72. Lombardo A, Cesana D, Genovese P, Di Stefano B, Provasi E, Colombo DF, NeriM, Magnani Z, Cantore A, Lo Riso P, et al. 2011. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 8: 861-869.
73. Maina N, Zhong L, Li X, Zhao W, Han Z, Bischof D, Aslanidi G, Zolotukhin S, Weigel-Van Aken KA, Rivers AE, et al. 2008. Optimization of recombinant adeno-associated viral vectors for human β-globin gene transfer and transgene expression. Hum Gene Ther 19: 365-375.
74. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, Sadelain M. 2000. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406: 82-86.
75. May C, Rivella S, Chadburn A, Sadelain M. 2002. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene. Blood 99: 1902-1908.
76. Mercola KE, Cline MJ. 1980. The potentials of inserting new genetic information. N Engl J Med 303: 1297-1300.
77. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, Brugman MH, Schambach A, Charrier S, Galy A, Thrasher AJ, et al. 2009. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919-1928.
78. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C, Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, et al. 2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
79. Montini E, Cesana D, Schmidt M, Sanvito F, Bartholomae CC, Ranzani M, Benedicenti F, Sergi LS, Ambrosi A, Ponzoni M, et al. 2009. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest 119: 964-975.
80. Mulligan RC, Howard BH, Berg P. 1979. Synthesis of rabbit β-globin in cultured monkey kidney cells following infection with a SV40 β-globin recombinant genome. Nature 277: 108-114.
81. Muramoto GG, Russell JL, Safi R, Salter AB, Himburg HA, Daher P, Meadows SK, Doan P, Storms RW, Chao NJ, et al. 2010. Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. Stem Cells 28: 523-534.
82. Naldini L. 2011. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12: 301-315.
83. Naldini L, Verma IM. 2000. Lentiviral vectors. Adv Virus Res 55: 599-609.
84. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
85. Negre O, Fusil F, Colomb C, Roth S, Gillet-Legrand B, Henri A, Beuzard Y, Bushman F, Leboulch P, Payen E. 2011. Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion. Blood 117: 5321-5331.
86. Nicolini FE, Imren S, Oh IH, Humphries RK, Leboulch P, Fabry ME, Nagel RL, Eaves CJ. 2002. Expression of a human β-globin transgene in erythroid cells derived from retrovirally transduced transplantable human fetal liver and cord blood cells. Blood 100: 1257-1264.
87. Nienhuis AW, Dunbar CE, Sorrentino BP. 2006. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13: 1031-1049.
88. Nishino T, Tubb J, Emery DW. 2006. Partial correction of murine β-thalassemia with a gammaretrovirus vector for human γ-globin. Blood Cells, Mol Dis 37: 1-7.
89. Novak U, Harris EA, Forrester W, Groudine M, Gelinas R. 1990. High-level β-globin expression after retroviral transfer of locus activation region-containing human β-globin gene derivatives into murine erythroleukemia cells. Proc Natl Acad Sci 87: 3386-3390.
90. Oh IH, Fabry ME, Humphries RK, Pawliuk R, Leboulch P, Hoffman R, Nagel RL, Eaves C. 2004. Expression of an anti-sickling β-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells. Exp Hematol 32: 461-469.
91. Orkin SH, Motulsky AG. 1995. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. http: //www. nih. gov/news/panelrep. html.
92. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, Glimm H, Kühlcke K, Schilz A, Kunkel H, et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401-409.
93. Pai S-Y, Notarangelo LD, Harris C, Cattaneo F, Wladkowski M, Armant M, KaoGS, Wielgosz M, Nienhuis AW, Modlich U, et al. 2011. Somatic gene therapy for X-linked severe combined immunodeficiency using a self-inactivating modified gammaretroviral vector results in an improved preclinical safety profile and early clinical efficacy in a human patient. Blood 118: 80.
94. Palstra RJ, de Laat W, Grosveld F. 2008. β-globin regulation and long-range interactions. Adv Genet 61: 107-142.
95. Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, et al. 2011. Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 29: 73-78.
96. Pászty C, Brion CM, Manci E, Witkowska HE, Stevens ME, Mohandas N, RubinEM. 1997. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278: 876-878.
97. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, AcharyaSA, Ellis J, London IM, Eaves CJ, et al. 2001. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371.
98. Peled T, Shoham H, Aschengrau D, Yackoubov D, Frei G, Rosenheimer GN, Lerrer B, Cohen HY, Nagler A, Fibach E, et al. 2012. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol 40: 342-355.
99. Persons DA. 2010. Targeting β-thalassaemia. Nature 467: 277-278.
100. Persons DA, Allay ER, Sabatino DE, Kelly P, Bodine DM, Nienhuis AW. 2001. Functional requirements for phenotypic correction of murine β-thalassemia: Implications for human gene therapy. Blood 97: 3275-3282.
101. Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. 2003a. The degree of phenotypic correction of murine β-thalassemia intermedia following lentiviral-mediated transfer of a human γ-globin gene is influenced by chromosomal position effects and vector copy number. Blood 101: 2175-2183.
102. Persons DA, Allay ER, Sawai N, Hargrove PW, Brent TP, Hanawa H, NienhuisAW, Sorrentino BP. 2003b. Successful treatment of murine β-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 102: 506-513.
103. Perumbeti A, Higashimoto T, Urbinati F, Franco R, Meiselman HJ, Witte D, Malik P. 2009. A novel human γ-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: Critical determinants for successful correction. Blood 114: 1174-1185.
104. Pestina TI, Hargrove PW, Jay D, Gray JT, Boyd KM, Persons DA. 2009. Correction of murine sickle cell disease using γ-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol Ther 17: 245-252.
105. Pikaart MJ, Recillas-Targa F, Felsenfeld G. 1998. Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 12: 2852-2862.
106. Plavec I, Papayannopoulou T, Maury C, Meyer F. 1993. A human β-globin gene fused to the human β-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 81: 1384-1392.
107. Puthenveetil G, Scholes J, Carbonell D, Qureshi N, Xia P, Zeng L, Li S, Yu Y, HitiAL, Yee JK, et al. 2004. Successful correction of the human β-thalassemia major phenotype using a lentiviral vector. Blood 104: 3445-3453.
108. Ramezani A, Hawley TS, Hawley RG. 2008. Combinatiorial incorporation of enhancer-blocking components of chicken β-globin 5′HS4 and human T-cell receptor α/δ BEAD-1 Insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 26: 3257-3266.
109. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, Bell AC, Litt MD, West AG, Gaszner M, Felsenfeld G. 2002. Position-effect protection and enhancer blocking by the chicken β-globin insulator are separable activities. Proc Natl Acad Sci 99: 6883-6888.
110. Ren S, Wong BY, Li J, Luo XN, Wong PM, Atweh GF. 1996. Production of genetically stable high-titer retroviral vectors that carry a human γ-globin gene under the control of the α-globin locus control region. Blood 87: 2518-2524.
111. Rivella S, May C, Chadburn A, Rivière I, Sadelain M. 2003. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human β-globin gene transfer. Blood 101: 2932-2939.
112. Rivière I, Dunbar CE, Sadelain M. 2012. Hematopoietic stem cell engineering at a crossroads. Blood 119: 1107-1116.
113. Ronen K, Negre O, Roth S, Colomb C, Malani N, Denaro M, Brady T, Fusil F, Gillet-Legrand B, Hehir K, et al. 2011. Distribution of lentiviral vector integration sites in mice following therapeutic gene transfer to treat β-thalassemia. Mol Ther 19: 1273-1286.
114. Roselli EA, Mezzadra R, Frittoli MC, Maruggi G, Biral E, Mavilio F, MastropietroF, Amato A, Tonon G, Refaldi C, et al. 2010. Correction of β-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med 2: 315-328.
115. Ryu BY, Persons DA, Evans-Galea MV, Gray JT, Nienhuis AW. 2007. A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells. Blood Cells Mol Dis 39: 221-228.
116. Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, Nienhuis AW. 2008. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111: 1866-1875.
117. Sabatino DE, Seidel NE, Aviles-Mendoza GJ, Cline AP, Anderson SM, GallagherPG, Bodine DM. 2000. Long-term expression of γ-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human γ-globin gene fused to the ankyrin-1 promoter. Proc Natl Acad Sci 97: 13294-13299.
118. Sadelain M, Wang CH, Antoniou M, Grosveld F, Mulligan RC. 1995. Generation of a high-titer retroviral vector capable of expressing high levels of the human β-globin gene. Proc Natl Acad Sci 92: 6728-6732.
119. Sadelain M, Rivière I, Wang X, Boulad F, Prockop S, Giardina P, Maggio A, Galanello R, Locatelli F, Yannaki E. 2010. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β-thalassemia. Ann NY Acad Sci 1202: 52-58.
120. + cells for lentiviral gene transfer. Methods Mol Biol 506: 59-70.
121. Santoni de Sio FR, Gritti A, Cascio P, Neri M, Sampaolesi M, Galli C, Luban J, Naldini L. 2008. Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells. Stem Cells 26: 2142-2152.
122. + cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol Ther doi: 10. 1038/mt. 2012. 23.
123. Schoenfelder S, Sexton T, Chakalova L, Cope NF, Horton A, Andrews S, Kurukuti S, Mitchell JA, Umlauf D, Dimitrova DS, et al. 2010. Preferential associations between co-regulated genes reveal a transcriptional interactome in erythroid cells. Nat Genet 42: 53-61.
124. Schröder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110: 521-529.
125. Schwarzwaelder K, Howe SJ, Schmidt M, Brugman MH, Deichmann A, Glimm H, Schmidt S, Prinz C, Wissler M, King DJ, et al. 2007. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117: 2241-2249.
126. Seggewiss R, Pittaluga S, Adler RL, Guenaga FJ, Ferguson C, Pilz IH, Ryu B, Sorrentino BP, Young WS III., Donahue RE, et al. 2006. Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107: 3865-3867.
127. Shaw KL, Kohn DB. 2011. A tale of two SCIDs. Sci Transl Med 3: 97ps36.
128. Sirven A, Pflumio F, Zennou V, Titeux M, Vainchenker W, Coulombel L, Dubart-Kupperschmitt A, Charneau P. 2000. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 96: 4103-4110.
129. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, SchmidtM, Krämer A, Schwäble J, Glimm H, et al. 2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 198-204.
130. Sutton RE, Reitsma MJ, Uchida N, Brown PO. 1999. Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J Virol 73: 649-660.
131. Takekoshi KJ, Oh YH, Westerman KW, London IM, Leboulch P. 1995. Retroviral transfer of a human β-globin/δ-globin hybrid gene linked to β locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease. Proc Natl Acad Sci 92: 3014-3018.
132. Thornhill SI, Schambach A, Howe SJ, Ulaganathan M, Grassman E, Williams D, Schiedlmeier B, Sebire NJ, Gaspar HB, Kinnon C, et al. 2008. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol Ther 16: 590-598.
133. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, Blanche S, Davies EG, Parsley K, Gilmour K, King D, Howe S, Sinclair J, et al. 2005. Failure of SCID-X1 gene therapy in older patients. Blood 105: 4255-4257.
134. Tuan D, London IM. 1984. Mapping of DNase I-hypersensitive sites in the upstream DNA of human embryonic ε-globin gene in K562 leukemia cells. Proc Natl Acad Sci 81: 2718-2722.
135. Tuan D, Solomon W, Li Q, London IM. 1985. The "β-like-globin" gene domain in human erythroid cells. Proc Natl Acad Sci 82: 6384-6388.
136. 1 human hematopoietic stem cells. Proc Natl Acad Sci 95: 11939-11944.
137. Urbinati F, Arumugam P, Higashimoto T, Perumbeti A, Mitts K, Xia P, Malik P. 2009. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3′LTR. Mol Ther 17: 1527-1536.
138. Verhoeyen E, Relouzat F, Cambot M, Costa C, Nègre D, Legrand F, Joubert C, Le Grand R, Cosset FL, Leboulch P, et al. 2012. Stem cell factor-displaying SIV vectors together with a low conditioning regimen allow for long-term engraftment of gene marked autologous hemato-poietic stem cells in macaques. Hum Gene Ther 23: 754-768.
139. Walsh CE, Liu JM, Xiao X, Young NS, Nienhuis AW, Samulski RJ. 1992. Regulated high level expression of a human γ-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci 89: 7257-7261.
140. Weatherall DJ. 1988. The slow road to gene therapy. Nature 331: 13-14.
141. West AG, Huang S, Gaszner M, Litt MD, Felsenfeld G. 2004. Recruitment of histone modifications by USF proteins at a vertebrate barrier element. Mol Cell 16: 453-463.
142. + cells after lentiviral vector-mediated gene transfer. Blood 117: 2817-2826.
143. Wilber A, Nienhuis AW, Persons DA. 2011b. Transcriptional regulation of fetal to adult hemoglobin switching: New therapeutic opportunities. Blood 117: 3945-3953.
144. Wu C, Dunbar CE. 2011. Stem cell gene therapy: The risks of insertional mutagenesis and approaches to minimize genotoxicity. Front Med 5: 356-371.
145. Wu X, Li Y, Crise B, Burgess SM. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749-1751.
146. 0-thalassemia. Proc Natl Acad Sci 92: 11608-11612.
147. Yannaki E, Papayannopoulou T, Jonlin E, Zervou F, Karponi G, Xagorari A, Becker P, Psatha N, Batsis I, Kaloyannidis P, et al. 2012. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: Results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther 20: 230-238.
148. Yu SF, von Rüden T, Kantoff PW, Garber C, Seiberg M, Rüther U, Anderson WF, Wagner EF, Gilboa E. 1986. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci 83: 3194-3198.
149. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. 2000. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101: 173-185.
150. Zhao H, Pestina TI, Nasimuzzaman M, Mehta P, Hargrove PW, Persons DA. 2009. Amelioration of murine β-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both γ-globin and the MGMT drug-resistance gene. Blood 113: 5747-5756.
151. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.